The Medical Letter on Drugs and Therapeutics
Edluar - A New Sublingual Formulation of Zolpidem
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem (Ambien, and others), has been approved by the FDA for treatment of insomnia.

PHARMACOKINETICS — The peak serum concentrations (Cmax) and area under the time-concentration curve (AUC) of the sublingual tablet are similar to those of immediate-release (IR) tablets, and they are considered bioequivalent. The time to maximum serum concentrations (Tmax) is also similar. As with the IR tablets, the AUC and Cmax of the sublingual tablets decrease and Tmax increases when they are taken 20 minutes after eating, suggesting to some Medical Letter consultants that the sublingual tablet may not be absorbed sublingually or elsewhere in the oral cavity, and may have to be swallowed to reach the systemic circulation.

CLINICAL STUDIES — The sublingual and IR tablets were compared in ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Edluar - A New Sublingual Formulation of Zolpidem
Article code: 1336b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian